Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
Identifieur interne : 004216 ( Main/Exploration ); précédent : 004215; suivant : 004217Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
Auteurs : C. Roux [France] ; L. C. Hofbauer [Allemagne] ; P. R. Ho [États-Unis] ; J. D. Wark [Australie] ; M. C. Zillikens [Pays-Bas] ; A. Fahrleitner-Pammer [Autriche] ; F. Hawkins [Espagne] ; M. Micaelo [Portugal] ; S. Minisola [Italie] ; N. Papaioannou [Grèce] ; M. Stone [Royaume-Uni] ; I. Ferreira [États-Unis] ; S. Siddhanti [États-Unis] ; R. B. Wagman [États-Unis] ; J. P. Brown [Canada]Source :
- Bone : (New York, NY) [ 8756-3282 ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Femme.
English descriptors
- KwdEn :
Abstract
Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were treatment-naïve or previously treated with alendronate, denosumab was associated with greater gains in bone mineral density (BMD) and decreases in bone turnover markers when compared with alendronate-treated subjects. This trial was designed to compare the efficacy and safety of denosumab with risedronate over 12 months in postmenopausal women who transitioned from daily or weekly alendronate treatment and were considered to be suboptimally adherent to therapy. In this randomized, open-label study, postmenopausal women aged ≥55 years received denosumab 60 mg subcutaneously every 6 months or risedronate 150 mg orally every month for 12 months. Endpoints included percentage change from baseline in total hip BMD (primary endpoint), femoral neck, and lumbar spine BMD at month 12, and percentage change from baseline in sCTX-1 at months 1 and 6. Safety was also assessed. A total of 870 subjects were randomized (435, risedronate; 435, denosumab) who had a mean (SD) age of 67.7 (6.9) years, mean (SD) BMD T-scores of - 1.6 (0.9), - 1.9 (0.7), and - 2.2 (1.2) at the total hip, femoral neck, and lumbar spine, respectively, and median sCTX-1 of 0.3 ng/mL at baseline. At month 12, denosumab significantly increased BMD compared with risedronate at the total hip (2.0% vs 0.5%), femoral neck (1.4% vs 0%), and lumbar spine (3.4% vs 1.1 %; p < 0.0001 at all sites). Denosumab significantly decreased sCTX-l compared with risedronate at month 1 (median change from baseline of - 78% vs -17%; p < 0.0001) and month 6 (-61% vs - 23%; p < 0.0001). Overall and serious adverse events were similar between groups. In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover.
Affiliations:
- Allemagne, Australie, Autriche, Canada, Espagne, France, Grèce, Italie, Pays-Bas, Portugal, Royaume-Uni, États-Unis
- Attique (région), Communauté de Madrid, District de Dresde, Hollande-Méridionale, Latium, Saxe (Land), Victoria (État), Île-de-France
- Athènes, Dresde, Melbourne, Paris, Rome, Rotterdam
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000533
- to stream PascalFrancis, to step Curation: 005925
- to stream PascalFrancis, to step Checkpoint: 000361
- to stream Main, to step Merge: 004285
- to stream Main, to step Curation: 004216
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study</title><author><name sortKey="Roux, C" sort="Roux, C" uniqKey="Roux C" first="C." last="Roux">C. Roux</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Descartes University, Department of Rheumatology, Cochin Hospital, 27 rue du Faubourg Saint Jacques</s1><s2>75014 Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>75014 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Hofbauer, L C" sort="Hofbauer, L C" uniqKey="Hofbauer L" first="L. C." last="Hofbauer">L. C. Hofbauer</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Dresden University of Technology Medical Center, Division of Endocrinology and Bone Diseases, Fetscherstr. 74</s1><s2>01307 Dresden</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Ho, P R" sort="Ho, P R" uniqKey="Ho P" first="P. R." last="Ho">P. R. Ho</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Wark, J D" sort="Wark, J D" uniqKey="Wark J" first="J. D." last="Wark">J. D. Wark</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>The University of Melbourne, Department of Medicine (Royal Melbourne Hospital), Head, Bone & Mineral Medicine</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Zillikens, M C" sort="Zillikens, M C" uniqKey="Zillikens M" first="M. C." last="Zillikens">M. C. Zillikens</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Internal Medicine, Erasmus Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Fahrleitner Pammer, A" sort="Fahrleitner Pammer, A" uniqKey="Fahrleitner Pammer A" first="A." last="Fahrleitner-Pammer">A. Fahrleitner-Pammer</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Medizinische Universitaet Graz</s1><s2>Graz</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Medizinische Universitaet Graz</wicri:noRegion></affiliation></author><author><name sortKey="Hawkins, F" sort="Hawkins, F" uniqKey="Hawkins F" first="F." last="Hawkins">F. Hawkins</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>University Hospital 12 Octubre, Ctra. Andalucía Km 5,4</s1><s2>28041 Madrid</s2><s3>ESP</s3><sZ>7 aut.</sZ></inist:fA14><country>Espagne</country><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Micaelo, M" sort="Micaelo, M" uniqKey="Micaelo M" first="M." last="Micaelo">M. Micaelo</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Instituto Portugues de Reumatologia</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>8 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Instituto Portugues de Reumatologia</wicri:noRegion></affiliation></author><author><name sortKey="Minisola, S" sort="Minisola, S" uniqKey="Minisola S" first="S." last="Minisola">S. Minisola</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Internal Medicine and Medical Diciplines, "Sapienza" Università di Roma</s1><s2>Rome</s2><s3>ITA</s3><sZ>9 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Papaioannou, N" sort="Papaioannou, N" uniqKey="Papaioannou N" first="N." last="Papaioannou">N. Papaioannou</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Laboratory for the Research of Musculoskeletal System University of Athens, Medical School. "KAT' Hospital</s1><s2>Athens</s2><s3>GRC</s3><sZ>10 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Stone, M" sort="Stone, M" uniqKey="Stone M" first="M." last="Stone">M. Stone</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Bone Research Unit, Cardiff University Academic Centre, University Hospital of Llandough</s1><s2>Penarth</s2><s3>GBR</s3><sZ>11 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Penarth</wicri:noRegion></affiliation></author><author><name sortKey="Ferreira, I" sort="Ferreira, I" uniqKey="Ferreira I" first="I." last="Ferreira">I. Ferreira</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Siddhanti, S" sort="Siddhanti, S" uniqKey="Siddhanti S" first="S." last="Siddhanti">S. Siddhanti</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Wagman, R B" sort="Wagman, R B" uniqKey="Wagman R" first="R. B." last="Wagman">R. B. Wagman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Brown, J P" sort="Brown, J P" uniqKey="Brown J" first="J. P." last="Brown">J. P. Brown</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Laval University, CHU de Québec (CHUL), Room S-763, 2705 Laurier boulevard</s1><s2>Québec City, QC G1V 4G2</s2><s3>CAN</s3><sZ>15 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec City, QC G1V 4G2</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0062999</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0062999 INIST</idno><idno type="RBID">Pascal:14-0062999</idno><idno type="wicri:Area/PascalFrancis/Corpus">000533</idno><idno type="wicri:Area/PascalFrancis/Curation">005925</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000361</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000361</idno><idno type="wicri:doubleKey">8756-3282:2014:Roux C:denosumab:compared:with</idno><idno type="wicri:Area/Main/Merge">004285</idno><idno type="wicri:Area/Main/Curation">004216</idno><idno type="wicri:Area/Main/Exploration">004216</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study</title><author><name sortKey="Roux, C" sort="Roux, C" uniqKey="Roux C" first="C." last="Roux">C. Roux</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Paris Descartes University, Department of Rheumatology, Cochin Hospital, 27 rue du Faubourg Saint Jacques</s1><s2>75014 Paris</s2><s3>FRA</s3><sZ>1 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hofbauer, L C" sort="Hofbauer, L C" uniqKey="Hofbauer L" first="L. C." last="Hofbauer">L. C. Hofbauer</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Dresden University of Technology Medical Center, Division of Endocrinology and Bone Diseases, Fetscherstr. 74</s1><s2>01307 Dresden</s2><s3>DEU</s3><sZ>2 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Dresde</region><settlement type="city">Dresde</settlement></placeName></affiliation></author><author><name sortKey="Ho, P R" sort="Ho, P R" uniqKey="Ho P" first="P. R." last="Ho">P. R. Ho</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Wark, J D" sort="Wark, J D" uniqKey="Wark J" first="J. D." last="Wark">J. D. Wark</name><affiliation wicri:level="4"><inist:fA14 i1="04"><s1>The University of Melbourne, Department of Medicine (Royal Melbourne Hospital), Head, Bone & Mineral Medicine</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Zillikens, M C" sort="Zillikens, M C" uniqKey="Zillikens M" first="M. C." last="Zillikens">M. C. Zillikens</name><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Department of Internal Medicine, Erasmus Medical Center</s1><s2>Rotterdam</s2><s3>NLD</s3><sZ>5 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Fahrleitner Pammer, A" sort="Fahrleitner Pammer, A" uniqKey="Fahrleitner Pammer A" first="A." last="Fahrleitner-Pammer">A. Fahrleitner-Pammer</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Medizinische Universitaet Graz</s1><s2>Graz</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Medizinische Universitaet Graz</wicri:noRegion></affiliation></author><author><name sortKey="Hawkins, F" sort="Hawkins, F" uniqKey="Hawkins F" first="F." last="Hawkins">F. Hawkins</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>University Hospital 12 Octubre, Ctra. Andalucía Km 5,4</s1><s2>28041 Madrid</s2><s3>ESP</s3><sZ>7 aut.</sZ></inist:fA14><country>Espagne</country><placeName><region nuts="2" type="communauté">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Micaelo, M" sort="Micaelo, M" uniqKey="Micaelo M" first="M." last="Micaelo">M. Micaelo</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Instituto Portugues de Reumatologia</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>8 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Instituto Portugues de Reumatologia</wicri:noRegion></affiliation></author><author><name sortKey="Minisola, S" sort="Minisola, S" uniqKey="Minisola S" first="S." last="Minisola">S. Minisola</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Internal Medicine and Medical Diciplines, "Sapienza" Università di Roma</s1><s2>Rome</s2><s3>ITA</s3><sZ>9 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Papaioannou, N" sort="Papaioannou, N" uniqKey="Papaioannou N" first="N." last="Papaioannou">N. Papaioannou</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Laboratory for the Research of Musculoskeletal System University of Athens, Medical School. "KAT' Hospital</s1><s2>Athens</s2><s3>GRC</s3><sZ>10 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Stone, M" sort="Stone, M" uniqKey="Stone M" first="M." last="Stone">M. Stone</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Bone Research Unit, Cardiff University Academic Centre, University Hospital of Llandough</s1><s2>Penarth</s2><s3>GBR</s3><sZ>11 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Penarth</wicri:noRegion></affiliation></author><author><name sortKey="Ferreira, I" sort="Ferreira, I" uniqKey="Ferreira I" first="I." last="Ferreira">I. Ferreira</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Siddhanti, S" sort="Siddhanti, S" uniqKey="Siddhanti S" first="S." last="Siddhanti">S. Siddhanti</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Wagman, R B" sort="Wagman, R B" uniqKey="Wagman R" first="R. B." last="Wagman">R. B. Wagman</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Amgen Inc.</s1><s2>Thousand Oaks, CA</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Amgen Inc.</wicri:noRegion></affiliation></author><author><name sortKey="Brown, J P" sort="Brown, J P" uniqKey="Brown J" first="J. P." last="Brown">J. P. Brown</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Laval University, CHU de Québec (CHUL), Room S-763, 2705 Laurier boulevard</s1><s2>Québec City, QC G1V 4G2</s2><s3>CAN</s3><sZ>15 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec City, QC G1V 4G2</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Bone : (New York, NY)</title><title level="j" type="abbreviated">Bone : (NY NY)</title><idno type="ISSN">8756-3282</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Bone : (New York, NY)</title><title level="j" type="abbreviated">Bone : (NY NY)</title><idno type="ISSN">8756-3282</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alendronic acid</term><term>Antiosteoclastic agent</term><term>Antiosteoporotic</term><term>Bone mineral density</term><term>Bone remodeling</term><term>Denosumab</term><term>Immunomodulator</term><term>Morphology</term><term>Osteoporosis</term><term>Postmenopause</term><term>Risedronic acid</term><term>Toxicity</term><term>Treatment</term><term>Woman</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dénosumab</term><term>Acide risédronique</term><term>Acide alendronique</term><term>Postménopause</term><term>Femme</term><term>Traitement</term><term>Toxicité</term><term>Ostéoporose</term><term>Densité minérale osseuse</term><term>Remodelage osseux</term><term>Morphologie</term><term>Immunomodulateur</term><term>Antiostéoporotique</term><term>Antiostéoclastique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Femme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were treatment-naïve or previously treated with alendronate, denosumab was associated with greater gains in bone mineral density (BMD) and decreases in bone turnover markers when compared with alendronate-treated subjects. This trial was designed to compare the efficacy and safety of denosumab with risedronate over 12 months in postmenopausal women who transitioned from daily or weekly alendronate treatment and were considered to be suboptimally adherent to therapy. In this randomized, open-label study, postmenopausal women aged ≥55 years received denosumab 60 mg subcutaneously every 6 months or risedronate 150 mg orally every month for 12 months. Endpoints included percentage change from baseline in total hip BMD (primary endpoint), femoral neck, and lumbar spine BMD at month 12, and percentage change from baseline in sCTX-1 at months 1 and 6. Safety was also assessed. A total of 870 subjects were randomized (435, risedronate; 435, denosumab) who had a mean (SD) age of 67.7 (6.9) years, mean (SD) BMD T-scores of - 1.6 (0.9), - 1.9 (0.7), and - 2.2 (1.2) at the total hip, femoral neck, and lumbar spine, respectively, and median sCTX-1 of 0.3 ng/mL at baseline. At month 12, denosumab significantly increased BMD compared with risedronate at the total hip (2.0% vs 0.5%), femoral neck (1.4% vs 0%), and lumbar spine (3.4% vs 1.1 %; p < 0.0001 at all sites). Denosumab significantly decreased sCTX-l compared with risedronate at month 1 (median change from baseline of - 78% vs -17%; p < 0.0001) and month 6 (-61% vs - 23%; p < 0.0001). Overall and serious adverse events were similar between groups. In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>Canada</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Italie</li><li>Pays-Bas</li><li>Portugal</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Attique (région)</li><li>Communauté de Madrid</li><li>District de Dresde</li><li>Hollande-Méridionale</li><li>Latium</li><li>Saxe (Land)</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Athènes</li><li>Dresde</li><li>Melbourne</li><li>Paris</li><li>Rome</li><li>Rotterdam</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Roux, C" sort="Roux, C" uniqKey="Roux C" first="C." last="Roux">C. Roux</name></region></country><country name="Allemagne"><region name="Saxe (Land)"><name sortKey="Hofbauer, L C" sort="Hofbauer, L C" uniqKey="Hofbauer L" first="L. C." last="Hofbauer">L. C. Hofbauer</name></region></country><country name="États-Unis"><noRegion><name sortKey="Ho, P R" sort="Ho, P R" uniqKey="Ho P" first="P. R." last="Ho">P. R. Ho</name></noRegion><name sortKey="Ferreira, I" sort="Ferreira, I" uniqKey="Ferreira I" first="I." last="Ferreira">I. Ferreira</name><name sortKey="Siddhanti, S" sort="Siddhanti, S" uniqKey="Siddhanti S" first="S." last="Siddhanti">S. Siddhanti</name><name sortKey="Wagman, R B" sort="Wagman, R B" uniqKey="Wagman R" first="R. B." last="Wagman">R. B. Wagman</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Wark, J D" sort="Wark, J D" uniqKey="Wark J" first="J. D." last="Wark">J. D. Wark</name></region></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Zillikens, M C" sort="Zillikens, M C" uniqKey="Zillikens M" first="M. C." last="Zillikens">M. C. Zillikens</name></region></country><country name="Autriche"><noRegion><name sortKey="Fahrleitner Pammer, A" sort="Fahrleitner Pammer, A" uniqKey="Fahrleitner Pammer A" first="A." last="Fahrleitner-Pammer">A. Fahrleitner-Pammer</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Hawkins, F" sort="Hawkins, F" uniqKey="Hawkins F" first="F." last="Hawkins">F. Hawkins</name></region></country><country name="Portugal"><noRegion><name sortKey="Micaelo, M" sort="Micaelo, M" uniqKey="Micaelo M" first="M." last="Micaelo">M. Micaelo</name></noRegion></country><country name="Italie"><region name="Latium"><name sortKey="Minisola, S" sort="Minisola, S" uniqKey="Minisola S" first="S." last="Minisola">S. Minisola</name></region></country><country name="Grèce"><region name="Attique (région)"><name sortKey="Papaioannou, N" sort="Papaioannou, N" uniqKey="Papaioannou N" first="N." last="Papaioannou">N. Papaioannou</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Stone, M" sort="Stone, M" uniqKey="Stone M" first="M." last="Stone">M. Stone</name></noRegion></country><country name="Canada"><noRegion><name sortKey="Brown, J P" sort="Brown, J P" uniqKey="Brown J" first="J. P." last="Brown">J. P. Brown</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004216 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004216 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0062999
|texte= Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
}}
| This area was generated with Dilib version V0.6.33. |  |